Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Armata Pharmaceuticals Inc

ARMP ✗ NOT COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$5.82

▼ -0.34%

Market Cap $216.40M · Vol 6.58K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$216.40M

Micro Cap

Div Yield

N/A

EPS Growth

+59.89%

YoY

RSI (14)

68.21

Momentum

Beta

1.36

vs Market

52W High

$16.34

64.38% below

52W Low

$2.79

108.60% above

Volume

6.58K

Avg 15.56K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

32.36%

Public shares

Shariah Compliance8 STANDARDS

✗ Armata Pharmaceuticals Inc (ARMP) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARMP pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.63%

+23.57%

-23.12%

-45.09%

YTD

-7.32%

+106.38%

+95.30%

+51.96%

Financials & Valuation

TTM · Annual

Total Revenue	$4.90M
Net Income	$-173,799,000.00
Revenue Growth (YoY)	+15.72%
Gross Margin	100.00%
Operating Margin	-636.66%
Net Profit Margin	-3,544.03%
ROE	N/A
ROA · ROIC	-212.83% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	46.41
P/B	N/A
P/FCF	N/A
EPS Growth	+59.89%
Outstanding Shares	37.18M

Technical Indicators

50-Day SMA	$4.99
200-Day SMA	$7.50
RSI (14)	68.21
Beta	1.36
52-Week High	$16.34
52-Week Low	$2.79

Volume Today	6.58K
Avg Daily Volume (30D)	15.56K
Relative Volume	0.42x
Volatility (10D)	55.30
Volatility (30D)	98.88
Free Float	32.36%

Analyst Consensus

BUY

Current Price $5.82

Mean Target $17.50

52W Low$2.79 52W High$16.34

Current

Target

$2.79 $16.34

Current Analyst target

+200.69% upside potential · 2 analysts

Identifiers

ExchangeNYSE American

FIGIBBG001S5WNR0

ISINUS04216R1023

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -0.41% ARGX argenx SE -2.52% INSM Insmed Inc -1.11% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.